300289 Beijing Leadman Biochemistry
- 4.09
- +0.11+2.76%
Beijing Leadman Biochemistry News
Beijing Leadman Biochemistry (300289.SZ): The company's production of chemical raw materials does not include proteases.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interactive platform that the company currently does not have any reagent products available for detecting Klebsiella pneumoniae with high toxicity. The biochemical raw materials produced by the company do not contain proteases.
Beijing Leadman Biochemistry (300289.SZ): Currently not involved in anthrax testing reagent products.
On August 6, Gelunhui reported that Beijing Leadman Biochemistry (SZ.300289) stated on the investor interaction platform that the company is currently not involved in anthrax bacterial testing reagent products. At present, the company is using protease K as a raw material in the production of its testing reagent products.
Beijing Leadman Biochemistry (300289.SZ) is not subject to delisting risk warnings or other risk warnings.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform on July 23 that the company's current production and operation activities are all normal, and there is no situation of being subject to delisting risk warnings or other risk warnings. The stock price fluctuations in the secondary market are affected by various factors.
Beijing Leadman Biochemistry (300289.SZ) : JointMedicine repurchases 50% of the company's equity held in advance.
Leadman Biochemistry (300289.SZ) announced on July 9th that on November 8, 2022, the company signed the "Capital Increase Agreement of Shenzhen United Medical Technology Co., Ltd." and the "Shareholders Agreement of Shenzhen United Medical Technology Co., Ltd." with Shenzhen United Medical Technology Co., Ltd. (hereinafter referred to as "United Medical") and its shareholders. The company increased its capital by RMB 20 million of its own funds to United Medical and obtained 3.5088% equity. Recently, after negotiation between the company and United Medical, United Medical repurchased 50% of the company's equity held, while the company and United Medical reached an agreement with Guo Yong...
Beijing Leadman Biochemistry (300289.SZ): Currently there is no risk of special treatment (ST).
On July 4th, Gelonhui reported that Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company currently does not have special treat risk. Regarding the accounting treatment of accounts receivable, the company will strictly follow the Enterprise Accounting Standards, relevant regulations, and regulatory requirements.
Beijing Leadman Biochemistry (300289.SZ) has not yet involved in CXO business.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company is currently focusing on the in vitro diagnostics industry, and its business has not yet involved CXO. The company closely monitors market and industry development trends and actively seeks potential acquisition targets with business synergy.
Beijing Leadman Biochemistry (stock code 300289.SZ) has no plans to acquire Ting Sheng Technology at present.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform on June 20 that the company closely monitors market and industry development trends and seeks suitable investment symbols according to its own development plan, asset and fund size. The company currently has no plans to acquire Ting Sheng Technology.
Beijing Leadman Biochemistry (300289.SZ): Currently, all purchased financial products are guaranteed by commercial banks.
Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the current financial products purchased by the company are all principal guaranteed products offered by commercial banks.
Leadman (300289.SZ): The business does not currently involve proteasomes
Glonghui May 30 丨 Some investors asked Leadman (300289.SZ) on the investor interactive platform, “Does your company have proteasomes or layout?” The company replied that the company's business does not currently involve proteasomes.
Leadman (300289.SZ): There are currently no plans to directly invest in or acquire Yixi Biotech
On May 13, Ge Longhui | Leadman (300289.SZ) said on the investor interactive platform that the company's products in the field of immunotesting mainly include chemiluminescence kits and related diagnostic instruments. The company currently has no plans to directly invest in or acquire Yixi Biotech.
Leadman (300289.SZ) 2023 equity distribution: 0.1 yuan for every 10 shares, shares registered on May 16
Leadman (300289.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
Leadman (300289.SZ): Enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents
Gelonghui, May 8 | Leadman (300289.SZ) said on the investor interactive platform that the company's enzyme products are currently mainly used in the development and production of biochemical diagnostic reagents.
Leadman (300289.SZ): Not involved in the field of synthetic biology
Glonghui, May 6 | Leadman (300289.SZ) said on the investor interactive platform that the company is currently focusing on the in vitro diagnosis industry and has not yet involved the field of synthetic biology.
Leadman (300289.SZ): Net loss of 2.751 million yuan in the first quarter
Gelonghui, April 25 | Leadman (300289.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.6241 million yuan, down 12.51% year on year; net profit attributable to shareholders of listed companies - 27.51 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4.8794 million yuan; basic earnings per share - 0.0050 yuan.
Leadman (300289.SZ): Currently, e-commerce platforms and cross-border e-commerce platform promotion channels are not involved
Gelonghui, April 8 | Leadman (300289.SZ) said on the investor interactive platform that at this stage, the company promotes products and brands through various forms such as online marketing, public account tweets, academic marketing, thematic salons, expert satellite meetings, product promotion conferences, etc., and is actively building celebrity classrooms and scientific research courses as academic leading platforms to increase the recognition and satisfaction of end users with the company's products through academic brand influence, so as to strengthen academic construction of benchmark hospitals and in-depth cooperation with KOL experts. Currently, e-commerce platforms are not involved. Promotion channels with cross-border e-commerce platforms
Leadman (300289.SZ): Net profit of 15.337 million yuan in 2023, plan to distribute 0.1 yuan to 10 shares
On March 27, GLONGHUI | Leadman (300289.SZ) released its 2023 annual report. Operating income was 460 million yuan, down 34.62% year on year, and net profit was 15.337 million yuan, reversal of year-on-year losses. After deducting non-net profit of 8.79 million yuan, reversing losses year-on-year, with basic earnings of 0.03 yuan per share. A cash dividend of 0.1 yuan is distributed to all shareholders for every 10 shares.
Leadman (300289.SZ): The R&D and production base has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunodiagnostic reagents
Gelonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that the company's R&D and production base has adopted high industry standards and has built a large-scale, advanced and efficient fully automated diagnostic reagent production line. The assembly line includes four parallel production lines, which fully automate the preparation, canning, labeling and packaging, and has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immune diagnostic reagents. After being awarded the “2018 Beijing Intelligent Manufacturing Benchmark Enterprise”, the company passed the “2022 Beijing Intelligent Manufacturing Benchmark Enterprise (Figure)
Leadman (300289.SZ): Joint Medical, a shareholder, has launched a fully automated fluorescent staining intelligent analysis system (Gis3000 series), which can provide intelligent morphological panoramic solutions for gynecological inflammation
Glonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that United Medicine, in which the company invests, has launched a fully automated fluorescence staining intelligent analysis system (Gis3000 series), which can provide an intelligent morphological panoramic solution for gynecological inflammation. Full process automation combined with artificial intelligence AI technology can automatically smear, automatically dye, automatically dry, automatically focus, automatically scan, label, screen and output report functions for clinical use.
Leadman (300289.SZ): The current business focuses on the in vitro diagnosis industry and does not involve drugs
Gelonghui, March 15 | An investor asked Leadman (300289.SZ) on the investor interactive platform, “Please ask if your company has drugs with independent intellectual property rights developed through technical means such as chemical synthesis, genetic engineering, and antibody engineering.” The company replied that the company's current business focuses on the in vitro diagnosis industry and does not involve drugs.
Leadman (300289.SZ): Desai Systems obtained a medical device registration certificate for in vitro diagnostic reagents
On March 14, Gelonghui Leadman (300289.SZ) announced that Desai Diagnostic Systems (Shanghai) Co., Ltd. (“Desai System”), a wholly-owned subsidiary of the company, recently obtained an in vitro diagnostic reagent “Medical Device Registration Certificate” issued by the Shanghai Drug Administration. The free fatty acid determination kit (enzyme method) can accurately measure the level of free fatty acids in patients, providing strong support for early screening, diagnosis, and evaluation of treatment effects of diseases such as diabetes and cardiovascular disease.
Analysis
Price Target
No Data
